A phase I study of a novel therapeutic vaccine as perioperative treatment for patients with surgically resectable hepatocellular carcinoma: The YCP02 trial.

Masao NakajimaShoichi HazamaYukio TokumitsuYoshitaro ShindoHiroto MatsuiSatoshi MatsukumaYuki NakagamiKoji TamadaKeiko UdakaMichiie SakamotoAkira SaitoYasunari KoukiToshinari UematsuMing XuMichihisa IidaRyouichi TsunedomiNobuaki SuzukiShigeru TakedaTatsuya IokaShun DoiKazuhiko Sakamoto

Published in: Hepatology research : the official journal of the Japan Society of Hepatology (2023)

This novel therapeutic vaccine was safe as perioperative immunotherapy for patients with HCC and has the potential to strongly induce CD8+ T cells infiltration into tumors. This article is protected by copyright. All rights reserved.

Keyphrases

cardiac surgery
patients undergoing
clinical trial
study protocol
phase iii
randomized controlled trial
acute kidney injury
locally advanced
risk assessment
human health
replacement therapy